Flow Cytometry and Molecular Studies in Hematological Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 July 2026 | Viewed by 114
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recent advancements in the sensitivity and specificity of flow cytometry, alongside deeper insights into the molecular characteristics of hematological neoplasms, have significantly enhanced their classification. These improvements are shaping more accurate diagnoses and enabling better predictions for targeted treatments.
Lymphoma and leukemia tumorigenesis arise from a variety of mechanisms, including gene amplification, mutation, overexpression, microRNA misexpression, chromosomal aberrations, cell cycle dysregulation, and other complex regulatory pathways. A comprehensive understanding of these mechanisms, coupled with increasingly precise flow cytometry techniques, is driving the development of minimal residual disease evaluations and innovative therapeutic strategies. These advancements are particularly crucial for treating the most aggressive lymphoma/leukemia subtypes, which are often characterized by recurrence and resistance to conventional therapies.
This Special Issue will feature reviews and original research that present new perspectives on flow cytometry and molecular studies in hematological malignancies, with a focus on their diagnosis and therapeutic potential.
Dr. Kirill A. Lyapichev
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- flow cytometry
- molecular studies
- hematological neoplasms
- lymphoma
- leukemia
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
